Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 7
2003 7
2004 8
2005 7
2006 12
2007 14
2008 5
2009 15
2010 3
2011 10
2012 11
2013 6
2014 6
2015 9
2016 9
2017 8
2018 10
2019 13
2020 8
2021 3
2022 7
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

161 results

Results by year

Filters applied: . Clear all
Page 1
MYC Causes Multiple Myeloma Progression via Attenuating TP53-Induced MicroRNA-34 Expression.
Murakami Y, Kimura-Masuda K, Oda T, Matsumura I, Masuda Y, Ishihara R, Watanabe S, Kuroda Y, Kasamatsu T, Gotoh N, Takei H, Kobayashi N, Saitoh T, Murakami H, Handa H. Murakami Y, et al. Among authors: murakami h. Genes (Basel). 2022 Dec 29;14(1):100. doi: 10.3390/genes14010100. Genes (Basel). 2022. PMID: 36672841 Free PMC article.
Anti-CD38 antibody isatuximab monotherapy for Japanese individuals with relapsed/refractory multiple myeloma: An update of the phase 1/2 ISLANDs study.
Sunami K, Fuchida SI, Suzuki K, Ri M, Matsumoto M, Shimazaki C, Asaoku H, Shibayama H, Ishizawa K, Takamatsu H, Ikeda T, Maruyama D, Imada K, Uchiyama M, Kiguchi T, Iyama S, Murakami H, Onishi R, Tada K, Iida S. Sunami K, et al. Among authors: murakami h. Hematol Oncol. 2023 Aug;41(3):442-452. doi: 10.1002/hon.3105. Epub 2022 Dec 15. Hematol Oncol. 2023. PMID: 36433829 Clinical Trial.
Outcomes of poor peripheral blood stem cell mobilizers with multiple myeloma at the first mobilization: A multicenter retrospective study in Japan.
Miyamoto-Nagai Y, Mimura N, Tsukada N, Aotsuka N, Ri M, Katsuoka Y, Wakayama T, Suzuki R, Harazaki Y, Matsumoto M, Kumagai K, Miyake T, Ozaki S, Shono K, Tanaka H, Shimura A, Kuroda Y, Sunami K, Suzuki K, Yamashita T, Shimizu K, Murakami H, Abe M, Nakaseko C, Sakaida E. Miyamoto-Nagai Y, et al. Among authors: murakami h. EJHaem. 2022 Jul 21;3(3):838-848. doi: 10.1002/jha2.534. eCollection 2022 Aug. EJHaem. 2022. PMID: 36051061 Free PMC article.
Propensity-score matched analysis of the efficacy of maintenance/continuous therapy in newly diagnosed patients with multiple myeloma: a multicenter retrospective collaborative study of the Japanese Society of Myeloma.
Ozaki S, Handa H, Koiso H, Saitoh T, Sunami K, Ishida T, Suzuki K, Narita T, Iida S, Nakamura Y, Suzuki K, Nishimura N, Murakami H, Shimizu K. Ozaki S, et al. Among authors: murakami h. J Cancer Res Clin Oncol. 2022 Jan;148(1):191-203. doi: 10.1007/s00432-021-03668-6. Epub 2021 Jun 2. J Cancer Res Clin Oncol. 2022. PMID: 34080068
IDO2 rs10109853 polymorphism affects the susceptibility to multiple myeloma.
Kasamatsu T, Hashimoto N, Sakaya N, Awata-Shiraiwa M, Ishihara R, Murakami Y, Masuda Y, Gotoh N, Nagai K, Oda T, Yokohama A, Saitoh T, Handa H, Tsukamoto N, Hayashi K, Murakami H. Kasamatsu T, et al. Among authors: murakami h. Clin Exp Med. 2021 May;21(2):323-329. doi: 10.1007/s10238-020-00681-w. Epub 2021 Mar 12. Clin Exp Med. 2021. PMID: 33709342
161 results